Legal status in the United States
Is Exenatide legal?
Read at FDA, DEA and WADAPublished by PepVault
Exenatide is FDA-approved (Byetta, Bydureon and Bydureon BCise, first in 2005), is not a federally controlled substance, and is not named on WADA’s Prohibited List, as of November 18, 2026.
Exenatide at a glance
| Check | Status, read Nov 18, 2026 |
|---|---|
| FDA approval | Approved (Byetta, 2005) |
| Compounding | Component of an approved drug (503A condition) |
| DEA schedule | Not controlled |
| Sport (WADA) | Not named on the list |
FDA approval
Exenatide was FDA-approved as Byetta in 2005, then as Bydureon (2012) and Bydureon BCise (2017). On Drugs@FDA, read November 18, 2026, Bydureon, Bydureon BCise and Byetta’s first application are listed as discontinued, and Byetta is listed as a prescription drug under a second application (NDA 021919); Byetta’s label on DailyMed gives its pens marketing end dates of November 30 and December 31, 2026.
Byetta (injection)
Approved for blood sugar control, with diet and exercise, in adults with type 2 diabetes. NDA 021773, first approved April 28, 2005; discontinued.
- Drugs@FDA: Byetta, application 021773, U.S. Food and Drug Administration. Read .
- Byetta prescribing information on DailyMed, National Library of Medicine (DailyMed). Read .
Byetta (injection)
Approved for blood sugar control, with diet and exercise, in adults with type 2 diabetes. NDA 021919, first approved October 30, 2009.
- Drugs@FDA: Byetta, application 021919, U.S. Food and Drug Administration. Read .
- Byetta prescribing information on DailyMed, National Library of Medicine (DailyMed). Read .
Bydureon (weekly injection)
Approved for blood sugar control, with diet and exercise, in type 2 diabetes (adults and children 10 and older). NDA 022200, first approved January 27, 2012; discontinued.
- Drugs@FDA: Bydureon, application 022200, U.S. Food and Drug Administration. Read .
- Bydureon prescribing information (Drugs@FDA, 2025), U.S. Food and Drug Administration. Read .
Bydureon BCise (weekly injection)
Approved for blood sugar control, with diet and exercise, in type 2 diabetes (adults and children 10 and older). NDA 209210, first approved October 20, 2017; discontinued.
- Drugs@FDA: Bydureon BCise, application 209210, U.S. Food and Drug Administration. Read .
- Bydureon BCise prescribing information (Drugs@FDA, 2025), U.S. Food and Drug Administration. Read .
- Drugs@FDA: Byetta, application 021919, U.S. Food and Drug Administration. Read .
- Drugs@FDA data (openFDA): applications listing “EXENATIDE” as an active ingredient, U.S. Food and Drug Administration. Read .

Compounding
Exenatide is the active ingredient of FDA-approved drugs (Byetta, Bydureon). FDA’s page on bulk drug substances gives three conditions under section 503A for a substance a pharmacy compounds from, and one of them is being a component of an FDA-approved drug product; the 503A and 503B bulks lists don’t name exenatide.
The source: “Are components of FDA-approved drug products if an applicable USP or NF monograph does not exist”
- Bulk Drug Substances Used in Compounding (content current as of March 26, 2026), U.S. Food and Drug Administration. Read .
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (updated May 14, 2026), U.S. Food and Drug Administration. Read .
- 503B Bulk Drug Substances List (content current as of May 16, 2024), U.S. Food and Drug Administration. Read .
DEA schedule
It is not a federally controlled substance: its name is not in the DEA’s schedules (21 CFR Part 1308) or on the DEA’s alphabetical list of controlled substances.
- 21 CFR Part 1308, Schedules of Controlled Substances (eCFR, up to date as of November 16, 2026), Electronic Code of Federal Regulations. Read .
- Controlled Substances, Alphabetical Order (dated November 17, 2026), Drug Enforcement Administration, Diversion Control Division. Read .
Sport (WADA)
The 2026 Prohibited List doesn’t name exenatide or GLP-1 drugs, and S0, the class for unapproved substances, doesn’t reach an approved drug.
- World Anti-Doping Code International Standard, Prohibited List 2026 (in effect from January 1, 2026), World Anti-Doping Agency. Read .
What this means and doesn’t
This page reports what the agencies’ own pages said about Exenatide in the United States when we read them on November 18, 2026. These are records of regulators, not study evidence; for what the research shows, see the compound page.
It is not legal advice, and it doesn’t cover state laws or other countries, whose rules differ. Agencies change their lists, so each fact carries its date and a link to the page it came from.
Questions
Is Exenatide FDA approved?
Exenatide was FDA-approved as Byetta in 2005, then as Bydureon (2012) and Bydureon BCise (2017). On Drugs@FDA, read November 18, 2026, Bydureon, Bydureon BCise and Byetta’s first application are listed as discontinued, and Byetta is listed as a prescription drug under a second application (NDA 021919); Byetta’s label on DailyMed gives its pens marketing end dates of November 30 and December 31, 2026.
Is Exenatide a controlled substance?
It is not a federally controlled substance: its name is not in the DEA’s schedules (21 CFR Part 1308) or on the DEA’s alphabetical list of controlled substances.
Is Exenatide banned in sport?
The 2026 Prohibited List doesn’t name exenatide or GLP-1 drugs, and S0, the class for unapproved substances, doesn’t reach an approved drug.
What does FDA say about compounding Exenatide?
Exenatide is the active ingredient of FDA-approved drugs (Byetta, Bydureon). FDA’s page on bulk drug substances gives three conditions under section 503A for a substance a pharmacy compounds from, and one of them is being a component of an FDA-approved drug product; the 503A and 503B bulks lists don’t name exenatide.